Skip to main content
SpringerLink
Log in

Lipidstoffwechselstörungen

  • Chapter
  • First Online:
Braun-Falco’s Dermatologie, Venerologie und Allergologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 939 Accesses

Zusammenfassung

Lipidstoffwechselstörungen sind in allen Industrienationen sehr häufig. Sie sind multifaktoriell bedingt: Ursache ist die Kombination von genetischen Faktoren, erhöhter Kalorienzufuhr bzw. hyperinsulinotroper Ernährung, zu wenig Bewegung, Rauchen, Alkoholkonsum sowie Erkrankungen wie Diabetes mellitus oder metabolisches Syndrom; auch zahlreiche Arzneimittel können Lipidstoffwechselstörungen bedingen. Wichtigste Folge sind kardiovaskuläre Krankheiten, an der Haut jedoch können typische Veränderungen (Xanthome) auftreten, die – werden sie frühzeitig erkannt – als klinische Warnzeichen für eine ernste metabolische/kardiovaskuläre Grunderkrankung dienen können. Die verschiedenen Hautmanifestationen werden im Folgenden beschrieben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 369.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

Übersichtsarbeiten

  • Armstrong EJ, Krueger JG (2016) Lipoprotein metabolism and inflammation in patients with psoriasis. Am J Cardiol 118:603–609

    Article  CAS  PubMed  Google Scholar 

  • Banach M, Nikolic D, Rizzo M, Toth PP (2016) IMPROVE-IT: what have we learned? Curr Opin Cardiol 31:426–433

    Article  PubMed  Google Scholar 

  • Biesalski HK, Bischoff SC, Puchstein C (Hrsg) (2010) Ernährungsmedizin: Nach dem Curriculum Ernährungsmedizin der Bundesärztkammer und der DGE, 12. Aufl. Thieme Verlag, Stuttgart

    Google Scholar 

  • European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G et al (2011) SC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32:1769–1818

    Article  Google Scholar 

  • Gabcova-Balaziova D, Stanikova D, Vohnout B et al (2015) Molecular-genetic aspects of familial hypercholesterolemia. Endocr Regul 49:164–181

    Article  CAS  PubMed  Google Scholar 

  • Hegele RA, Ginsberg HN, Chapman MJ et al (2014) The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2:655–666

    Article  CAS  PubMed  Google Scholar 

  • Joseph L, Robinson JG (2015) Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and the future of lipid lowering therapy. Prog Cardiovasc Dis 58:19–31

    Article  PubMed  Google Scholar 

  • Klör H-U, Weizel A, Augustin M et al (2011) Beeinflussung des Fettstoffwechsels durch systemische Vitamin-A-Derivate – Welche Empfehlungen leiten sich daraus für die dermatologische Paxis ab? J Dtsch Dermatol Ges 9:600–607

    PubMed  Google Scholar 

  • Ray KK, Kastelein JJ, Boekholdt SM et al (2014) The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 35:960–968

    Article  PubMed  Google Scholar 

  • Ripatti P, Rämö JT, Söderlund S et al (2016) The contribution of GWAS loci in familial dyslipidemias. PLoS Genet 12:e1006078

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sabatine MS (2016) Advances in the treatment of dyslipidemia. Cleve Clin J Med 83:181–186

    Article  PubMed  Google Scholar 

  • Sabatine MS, Giugliano RP, Wiviott SD et al (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372:1500–1509

    Article  CAS  PubMed  Google Scholar 

  • Schaefer EJ, Tsunoda F, Diffenderfer M et al (2016) The measurement of lipids, lipoproteins, apolipoproteins, fatty acids, and sterols, and next generation sequencing for the diagnosis and treatment of lipid disorders. In: De Groot LJ, Beck-Peccoz P, Chrousos G et al (Hrsg) Endotext [Internet]. MDText.com, South Dartmouth

    Google Scholar 

  • Schmitz G, Grandl M (2008) Lipid homeostasis in macrophages – implications for atherosclerosis. Rev Physiol Biochem Pharmacol 160:93–125

    PubMed  CAS  Google Scholar 

  • Singh S, Bittner V (2015) Familial hypercholesterolemia – epidemiology, diagnosis, and screening. Curr Atheroscler Rep 17:482

    Article  CAS  PubMed  Google Scholar 

  • Szalat R, Arnulf B, Karlin L et al (2011) Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy. Blood 118:3777–3784

    Article  CAS  PubMed  Google Scholar 

  • Verbeek R, Hovingh GK, Boekholdt SM (2015) Non-high-density lipoprotein cholesterol: current status as cardiovascular marker. Curr Opin Lipidol 26:502–510

    Article  CAS  PubMed  Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft: Empfehlungen zur Therapie von Fettstoffwechselstörungen, Arzneiverordnung in der Praxis (2012) Bd 39, Sonderheft 1, 3. Aufl. S 1–51

    Google Scholar 

  • Yoo EG (2016) Sitosterolemia: a review and update of pathophysiology, clinical spectrum, diagnosis, and management. Ann Pediatr Endocrinol Metab 21:7–14

    Article  Google Scholar 

  • Zak A, Zeman M, Slaby A, Vecka M (2014) Xanthomas: clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 158:181–188

    Article  Google Scholar 

Xanthome und Xanthelasmen

  • Berge KE, Tian H, Graf GA et al (2000) Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporter. Science 290:1771–1775

    Article  CAS  PubMed  Google Scholar 

  • Bergman R (1998) Xanthelasma palpebrarum and risk of atherosclerosis. Int J Dermatol 37:343–345

    Article  CAS  PubMed  Google Scholar 

  • Cohen YK, Elpern DJ (2015) Diffuse normolipemic plane xanthoma associated with monoclonal gammopathy. Dermatol Pract Concept 5:65–67

    PubMed  PubMed Central  Google Scholar 

  • Cruz PD Jr, East C, Bergstresser PR (1988) Dermal, subcutaneous, and tendon xanthomas: diagnostic markers for specific lipoprotein disorders. J Am Acad Dermatol 19:95–111

    Article  PubMed  Google Scholar 

  • Guirado SS, Conejo-Mir JS, Muñoz MA et al (2007) Sitosterol xanthomatosis. J Eur Acad Dermatol Venereol 21:100–103

    Article  CAS  PubMed  Google Scholar 

  • Hofmann JJ, Zovein AC, Koh H et al (2010) Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: insights into Alagille syndrome. Development 137:4061–4072

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nair PA, Patel CR, Ganjiwale JD et al (2016) Xanthelasma palpebrarum with Arcus cornea: a clinical and biochemical study. Indian J Dermatol 61:295–300

    Article  PubMed  PubMed Central  Google Scholar 

  • Orsó E, Grandl M, Schmitz G (2011) Oxidized LDL-induced endolysosomal phospholipidosis and enzymatically modified LDL-induced foam cell formation determine specific lipid species modulation in human macrophages. Chem Phys Lipids 164:479–487

    Article  CAS  PubMed  Google Scholar 

  • Schmitz G, Langmann S (2006) The lipid flux rheostat: implications of lipid trafficing pathways. J Mol Med 84:262–265

    Article  CAS  PubMed  Google Scholar 

  • Wang H, Shi Y, Guan H et al (2016) Treatment of xanthelasma palpebrarum with intralesional pingyangmycin. Dermatol Surg 42:368–376

    Article  CAS  PubMed  Google Scholar 

  • Yoo EG (2016) Sitosterolemia: a review and update of pathophysiology, clinical spectrum, diagnosis, and management. Ann Pediatr Endocrinol Metab 21:7–14

    Article  Google Scholar 

  • Zak A, Zeman M, Slaby A, Vecka M (2014) Xanthomas: clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 158:181–188

    Article  Google Scholar 

Primäre Dyslipoproteinämien

  • Arca M, Zuliani G, Wilund K et al (2002) Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in AHR: a clinical and molecular genetic analysis. Lancet 359:841–847

    Article  CAS  PubMed  Google Scholar 

  • Bodzioch M, Orsó E, Klucken J et al (1999) The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 22:347–351

    Article  CAS  PubMed  Google Scholar 

  • Brown MS, Goldstein JL (1986) A receptor mediated pathway for cholesterol homeostasis. Science 232:34–47

    Article  CAS  Google Scholar 

  • De Graaf J, Veerkamp MJ, Stalenhoef AFH (2002) Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids. J R Soc Med 95:46–53

    Article  PubMed  PubMed Central  Google Scholar 

  • Oliva CP, Pisciotta L, Li Volti G et al (2005) Inherited apolipoprotein A-V deficiency in severe hypertiglyceridemia. Arterioscler Thromb Vasc Biol 25:411–417

    Article  CAS  Google Scholar 

  • Pajukanta P, Lilja HE, Sinsheimer JS et al (2004) Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 36:322–324

    Article  CAS  Google Scholar 

  • Peros E, Geroldi G, D’Angelo A et al (2004) Apolipoprotein (a) phenotypes are reliable biomarkers for familial aggregation of coronary heart disease. Int J Mol Med 13:243–247

    PubMed  CAS  Google Scholar 

  • Reimund M, Larsson M, Kovrov O et al (2015) Evidence for two distinct binding sites for lipoprotein lipase on glycosylphosphtidylinositol-anchored high density lipoprotein-binding protein 1 (GPIHP1). J Biol Chem 290:13919–13934

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Saleh M, Kamath BM, Chitayat D (2016) Alagille syndrome: clinical perspectives. Appl Clin Genet 9:75–82

    Article  PubMed  PubMed Central  Google Scholar 

  • Schmitz G, Orsó E (2015) Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects. Clin Res Cardiol Suppl 10:21–25

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Erstbeschreiber

  • Abifadel M, Varret M, Rabes JP et al (2003) Mutations in the PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34:154–156

    Article  CAS  PubMed  Google Scholar 

  • Alagille D, Odievre M, Gautier M, Dommergues JP (1975) Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental and sexual development, and cardiac murmur. J Pediatr 86:63–71

    Article  CAS  PubMed  Google Scholar 

  • Bhattacharyya AK, Connor WE (1973) β-Sitosterolemia and xanthomatosis: a newly described lipid storage disease in two sisters. J Clin Invest 52:9a

    Google Scholar 

  • Bodzioch M, Orso E, Klucken J et al (1999) The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 22:347–351

    Article  CAS  PubMed  Google Scholar 

  • Bürger M, Grütz O (1932) Über hepatosplenomegale Lipidose mit xanthomatösen Veränderungen in Haut und Schleimhaut. Arch Dermatol Syph 166:542–547

    Article  Google Scholar 

  • Fredrickson DS, Altrocchi PH, Avioli LV et al (1961) Tangier disease – combined clinical staff conference at the National Institutes of Health. Ann Intern Med 55:1016–1031

    Article  Google Scholar 

  • Fredrickson DS, Levy RI, Lees RS (1967) Fat transport in lipoproteins – an integrated approach to mechanism and disorders. N Engl J Med 276:32–44, 94–103, 148–156, 215–226, 273–281

    Article  Google Scholar 

  • Garcia CK, Wilund K, Arca M et al (2001) Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 292:1394–1398

    Article  CAS  PubMed  Google Scholar 

  • Gofman JW, DeLalla O, Glazier F et al (1954) The serum lipoprotein transport system in health, metabolic disorders, atherosclerosis and coronary heart disease. Plasma 2:413–428

    Google Scholar 

  • Goldstein JL, Brown MS (1973) Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity with overproduction of cholesterol. Proc Natl Acad Sci USA 20:2804–2806

    Article  Google Scholar 

  • Goldstein JL, Schrott HG, Hazzard WR et al (1973) Hyperlipidemia in coronary artery disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52:1533–1568

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Haddad L, Day IN, Hunt S et al (1999) Evidence for a third genetic locus causing familial hypercholesterolemia: a non-LDLR, non-APOB kindred. J Lipid Res 40:1113–1122

    PubMed  CAS  Google Scholar 

  • Havel R, Gordon RS (1960) Idiopathic hyperlipidemia: metabolic studies in an affected family. J Clin Invest 39:1777–1782

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Innerarity TL, Weisgraber KH, Arnold KS et al (1987) Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA 84:6919–6923

    Article  CAS  PubMed  Google Scholar 

  • Khachadurian AK, Uthman M (1973) Experiences with the homozygous cases of familial hypercholesterolemia. A report of 52 cases. Nutr Metab 15:132–140

    Article  CAS  PubMed  Google Scholar 

  • Mahley RW, Angelin B (1984) Type III hyperlipoproteinemia: recent insights into the genetic defect of familial dysbetalipoproteinemia. Adv Intern Med 29:385–411

    PubMed  CAS  Google Scholar 

  • Müller C (1938) Xanthomata, hypercholesterinemia, angina pectoris. Acta Med Scand Suppl 89:75–80

    Google Scholar 

  • Soria LF, Ludwig EH, Clarke HR et al (1989) Association between a specific apolipoprotein B mutation and familial defective apo B-100. Proc Natl Acad Sci USA 86:587–591

    Article  CAS  PubMed  Google Scholar 

  • Tada H, Kawashiri MA, Ohtani R et al (2011) A novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene. Atherosclerosis 219:663–666

    Article  CAS  PubMed  Google Scholar 

  • Thannhauser SJ, Magendantz H (1938) The different clinical groups of xanthomatous diseases: a clinical physiological study of 22 cases. Ann Intern Med 11:1662–1746

    Article  CAS  Google Scholar 

  • Utermann G, Jaeschke M, Menzel J (1975) Familial hyperlipoproteinemia type III: deficiency of a specific apolipoprotein (apo E-III) in the very-low-density lipoproteins. FEBS Lett 56:352–355

    Article  CAS  PubMed  Google Scholar 

  • Van Bogaert L, Scherer HJ, Epstein E (1937) Une forme cérébrale de la cholestérinose géneralisée. Masson, Paris

    Google Scholar 

  • Vega GL, Grundy SM (1986) In vitro evidence for reduced binding of low density lipoproteins to receptors as a cause of primary hypercholesterolemia. J Clin Invest 78:1410–1415

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Watson GH, Miller V (1973) Arteriohepatic dysplasia: familial pulmonary arterial stenosis with neonatal liver disease. Arch Dis Child 48:459–466

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Dermatologie, Umweltmedizin und Gesundheitstheorie, Universität Osnabrück, Osnabrück, Deutschland

    Bodo Melnik

  2. Hautarztpraxis, Eickhoffstr. 20, 33330, Gütersloh, Deutschland

    Bodo Melnik

Authors
  1. Bodo Melnik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bodo Melnik .

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Dermatologie und Allergologie, Universitätsklinikum München, München, Germany

    Gerd Plewig

  2. Klinik und Poliklinik für Dermatologie und Allergologie, Universitätsklinikum München, München, Germany

    Thomas Ruzicka

  3. Klinik für Dermatologie, Venerologie und Allergologie, J.W.Goethe-Universität, Frankfurt, Germany

    Roland Kaufmann

  4. Klinik für Dermatologie und Allergologie, Universitätsklinikum Marburg, Marburg, Germany

    Michael Hertl

Section Editor information

  1. Direktor der Klinik für Dermatologie, Venerologie und Allergologie, Klinikum der J.W.Goethe-Universität, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany

    Roland Kaufmann

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Melnik, B. (2018). Lipidstoffwechselstörungen. In: Plewig, G., Ruzicka, T., Kaufmann, R., Hertl, M. (eds) Braun-Falco’s Dermatologie, Venerologie und Allergologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-49544-5_89

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-49544-5_89

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-49543-8

  • Online ISBN: 978-3-662-49544-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation